Paxlovid (nirmatrelvir-ritonavir) is efficient at stopping hospitalization and demise from COVID-19, however few folks use it. A paper by SteelFisher et al. (2024) surveyed 1,430 American adults to seek out out why. Their survey revealed sufferers had a lack of expertise of the remedy in addition to misinformation concerning the remedy (amongst those that have been conscious of it). Particularly:
A majority of respondents (85 p.c) had no or low consciousness of Paxlovid, together with 31 p.c who had by no means heard of it. Even amongst those that have been conscious of the drug, many held misperceptions about its effectiveness (39 p.c), adversarial results (86 p.c), and requisite timing (61 p.c) that might result in underuse. Decrease consciousness and misperceptions have been extra frequent amongst medically susceptible and deprived populations who would possibly profit most from Paxlovid entry, together with adults unvaccinated in opposition to COVID-19, these with decrease ranges of training, and Black and Hispanic or Latino adults.
You’ll be able to learn the total paper right here.